Residual atypical intraepidermal melanocytic proliferation may predict melanoma diagnosis

Increasing proportions of atypical intraepidermal melanocytic proliferation on various parts of the body may increase the likelihood of a diagnostic change to melanoma after Mohs micrographic surgery, according to findings presented at the American Society for Dermatologic Surgery Annual Meeting.

Oncolytic virus boosts ipilimumab response in advanced melanoma

medwireNews: Combining the oncolytic virus talimogene laherparepvec with the immune checkpoint inhibitor ipilimumab significantly improves treatment response compared with ipilimumab alone in patients with advanced melanoma, phase II study data show.

Advanced melanoma: Groundbreaking trials could transform treatment

Results from two international clinical trials could transform the treatment of advanced melanoma, the deadliest skin cancer type.

Melanoma treatment trials good news for Far North Queensland

OUTCOMES from new clinical trials into melanoma treatment could transform the lives of Far North patients battling the disease.

Cancer in the News

Feature Articles

Slip, Slop, Slap: We need fresh messages about skin cancer prevention

The Australian health system is now spending just over $200 million each year on the diagnosis and treatment of melanoma.

Read the full story

Posted in Melanoma In The News, Information, Patient Information

Signaling Pathway Modulates Melanoma Response to Autophagy Inhibitors

Scientists identified a new link between autophagy and a key melanoma signaling pathway, in which changes in signaling may affect treatment response, according to a study published in Cancer Research.

Read the full story

Posted in Melanoma In The News, Information

Disease-Free Survival Gains Reported for Vemurafenib in Stage IIC-IIIB Melanoma

Adjuvant therapy with vemurafenib (Zelboraf) for high-risk melanoma led to mixed results, as patients with stage IIIC did not benefit, but those with earlier stage disease did, according to data reported at the 2017 ESMO Congress in Madrid.

Read the full story

Posted in Melanoma In The News, Information

Neoadjuvant Dabrafenib/Trametinib Leads to High pCR Rates in Bulky Resectable Melanoma, But Recurrences Are Common

Phase II results demonstrated that nearly half of patients with resectable stage IIIB/C BRAF V600-mutant melanoma achieved pathologic complete response (pCR) with neoadjuvant combination therapy consisting of dabrafenib (Tafinlar) and trametinib (Mekinist).

Read the full story

Posted in Melanoma In The News, Information

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories